OncoCyte provided additional details about the history of the Razor test, its timeline for making it commercially available, and plans for a follow-on study.
The partners will use Biolidics' circulating tumor cell retrieval system to evaluate the cells' utility as biomarkers of patient response to cancer treatment.
The Belgian oncology molecular diagnostics firm reported a 17 percent increase in product sales but said that sales of cartridges in the US were lower than expected.
Developed using the center's "industrialized" proteomics workflow, the panel identified patients up to a year before their diagnosis with 89 percent accuracy.
The firm, which is working to reaccelerate its test validation effort, incurred a loss of $5.4 million, or $.10 per share, slightly above the analysts' consensus estimate.
Researchers focused on candidate genes near expression quantitative trait loci identified by combining cancer susceptibility SNPs and available transcriptomic data.
In PLOS this week: variations in the way synonymous DNA codons are used in yeast, links between germline TP53 mutations and recurrent somatic mutations in bladder cancer, and more.
